Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155200 | 1.00 | NR1I2 (0.67) | NR1I2CA1CA2CES2CES1 | |
| SCHEMBL2155196 | 1.00 | NR1I2 (0.67) | NR1I2CA1CA2CES2CES1 | |
| SCHEMBL554922 | 0.81 | NR1I2 (1.00) | NR1I2CA1CA2CES2CES1 | |
| SCHEMBL6232157 | 0.81 | NR1I2 (1.00) | NR1I2CA1CA2CES2CES1 | |
| SCHEMBL554921 | 0.81 | NR1I2 (1.00) | NR1I2CA1CA2CES2CES1 | |
| SCHEMBL30786875 | 0.81 | CES2 (0.56) | CES2CES1KMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL29135808 | 0.81 | CES2 (0.56) | CES2CES1KMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL2154926 | 0.81 | CES2 (0.56) | CES2CES1KMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL2154922 | 0.81 | CES2 (0.56) | CES2CES1KMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL6653882 | 0.80 | CA1 (0.63) | CA1CA2CES2CES1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-8410176-B2 | Intermediate compounds and processes for the preparation of tapentadol and related compounds | MAPI PHARMA LTD. (IL) | 2013-04-02 | — | — | US | disclosed |
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LIMITED (IL) | 2012-11-08 | — | — | US | disclosed |
| EP-2519100-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | Mapi Pharma Limited (IL) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080736-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA HK LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | PNMT, OPRK1, CYP2E1 | NR1I2 285/4885CA1 1538/4885CA2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.